FDA — authorised 22 February 2005
- Application: NDA021269
- Marketing authorisation holder: VIATRIS
- Local brand name: CARDURA XL
- Indication: TABLET, EXTENDED RELEASE — ORAL
- Status: approved
🇺🇸 Doxazosin Mesylate, Extended Release in United States
FDA authorised Doxazosin Mesylate, Extended Release on 22 February 2005 · 1 US adverse-event reports
Marketing authorisation
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 1
Most-reported reactions
- Thrombocytopenia — 1 report (100%)
Other Urology approved in United States
Frequently asked questions
Is Doxazosin Mesylate, Extended Release approved in United States?
Yes. FDA authorised it on 22 February 2005.
Who is the marketing authorisation holder for Doxazosin Mesylate, Extended Release in United States?
VIATRIS holds the US marketing authorisation.